Jim Hollingshead - ResMed Insider

RMD -- USA Stock  

USD 109.33  0.52  0.48%

  President
Dr. Jim Hollingshead, Ph.D. is President Sleep Business of the Company. Mr. Hollingshead joined ResMed in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include the leadership of ResMed ventures and initiatives, the unit responsible for growing early stage businesses. In March 2013, he was appointed president Americas. Before joining us, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that Mr. Hollingshead was managing partner, west coast for Monitor Group, a global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world, and successfully launched and ran three different practices, including a panEuropean marketing strategy practice based in London
Age: 53  President Since 2017  Ph.D    
858-836-5000  http://www.resmed.com
Hollingshead holds an A.B. in history and international relations with highest distinction from Stanford University, and an M.A. and Ph.D in political science from the University of California at Berkeley, where he was awarded a graduate student fellowship by the National Science Foundation.

Management Efficiency

The company has Return on Asset of 9.58 % which means that on every $100 spent on asset it made $9.58 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.68 % implying that it generated $15.68 on every 100 dollars invested.
The company has 810 M in debt with debt to equity (D/E) ratio of 39.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 3.41 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Meredith HuetterEndologix
2016
John SaronBovie Medical Corporation
2011
Andreas FrankHill Rom Holdings
2011
Neil RydingHaemonetics Corporation
N/A
Stephen WetherupCantel Medical Corp
2016
Andrew FryeBaxter International
2017
David HelselHaemonetics Corporation
2013
Sandra JesseHaemonetics Corporation
2016
Marcus SchabackerBaxter International
2015
John DeFordBecton Dickinson and Company
2018
Deborah RasinHill Rom Holdings
2016
Jeffrey StelkEndologix
2004
Stanley BurhansHill Rom Holdings
2015
Laura NagelEndologix
2017
Richard WagnerHill Rom Holdings
2018
James MachekEndologix
2015
Brik EyreBaxter International
2017
Mary LadoneHill Rom Holdings
2018
Sean MartinBaxter International
2017
David WilsonHaemonetics Corporation
2017
Ludwig HantsonBaxter International
2010

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on BATS Exchange. It employs 6000 people.ResMed (RMD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Independent Director
Ronald Taylor, Lead Independent Director
Rob Douglas, President COO
Christopher Roberts, Independent Director
Gary Pace, Independent Director
Chris Roberts, Independent Director
Robert Douglas, Pres and COO
Agnes Lee, Senior Director - Investor Relations
Carol Burt, Independent Director
Rich Sulpizio, Independent Director
Peter Farrell, Non-Executive Chairman of the Board
Jim Hollingshead, President - Americas
Brett Sandercock, CFO and Principal Accounting Officer
Ron Taylor, Lead Independent Director
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit
Jack Wareham, Independent Director
Anne Reiser, President Europe
Karen Drexler, Director
Raj Sodhi, President ? Software as a Service (SaaS) Business and CTO
David Pendarvis, Chief Admin. Officer, Global General Counsel and Secretary
Richard Sulpizio, Independent Director
Michael Farrell, CEO and Director
Richard McHale, President ? Respiratory Care
Donald Darkin, President ? innovation & operations

Stock Performance Indicators

Current Sentiment - RMD

ResMed Investor Sentiment
Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
MSFT   
Purchased over 20 shares of
2 days ago
Traded for 106.27
F   
Purchased over 200 shares of
2 days ago
Traded for 10.56
GM   
Purchased over 70 shares of
2 days ago
Traded for 39.4
GOOG   
Purchased few shares of
2 days ago
Traded for 1184.91
C   
Purchased over 40 shares of
2 days ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">